The Online Investor
CBRX Buyback image

Columbia Laboratories, Inc. Buyback

OLI recorded this information on 3/7/2014

Company: Columbia Laboratories, Inc.
Buyback: CBRX buyback
Shares Announced Repurchased: 1,400,000.00
Buyback Details: Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that the Company has repurchased 1.4 million shares of its common stock, par value $0.01 per share, from Coventry Acquisition, LLC, a subsidiary of Actavis Inc. (Actavis), at $6.08 per share, which represents a 10.75% discount to the closing price on Thursday, March 6, 2014. The total purchase price was approximately $8.5 million. This transaction reduces the total issued and outstanding shares of common stock by about 11.5% from approximately 12.15 million to 10.75 million.

Juniper Pharmaceuticals is engaged in in the business of developing, licensing, manufacturing and selling to its marketing partners pharmaceutical products that utilize its drug delivery technologies to treat various medical conditions. Co.'s products include bioadhesive vaginal gel products for infertility, pregnancy support, amenorrhea, and other women's health conditions, and a bioadhesive buccal system for male hypogonadism. Co. has partnered or sold each of these products for commercialization in various regions of the world. All of the products Co. has developed utilize its Bioadhesive Delivery System, which consists principally of a polymer (polycarbophil) and an active ingredient.
Open the CBRX Page at The Online Investor »

Company Name: 
Juniper Pharmaceuticals Inc
Stock buyback: 
CBRX buyback
Drugs & Pharmaceuticals

Open the CBRX Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree CBRX Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (3.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

CBRX Buyback Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.